/
CTNM
$15.30+$0.32 (+2.14%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$563.6M
38M shares
52-week range
$6.56 – $16.91
84% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-0.10
Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
www.contineum-tx.com- Employees
- 51
- IPO / List date
- Apr 5, 2024
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds CTNM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 69,400 | $906.4K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CTNM yet.
